Verdejo J, Iniguez A, Polo R, Martinez ML, Inchaustegui L, Enriquez A, Gonzalez-Lahoz JM; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1994 Oct 4-7; 114.

Instituto de Salud Carlos III, Madrid, Spain.

We evaluate hepatobiliary complications and serological markers in viral hepatitis in a prospective study since February 1992. RESULTS: Patients 115 (55 AIDS - CDC 1993). Average follow-up 269.2 days (range 60-690). Sex: M 86/F 29. Average age 32 (range 21-69). Risk group: IVDU 76, Homosexual 28, Heterosexual 10, Transfusion 1. We obtained the following results: (I) Hepatobiliary complications 101 in 84 patients (84/115: 73%). Complications: chronic viral hepatitis 27 (21 HCV, 3 HBV,1 HCV+HBV, 1 HBV+HDV, 1 HBV+HCV+HDV); without filiation 18; mild alterations 16(GPT and/or GGT less than 1.5 times limit of normal); hepatotoxic agents 13; infectious diseases 10 (cholangitis/cholecystitis 6, tuberculosis 3, bacteremia 1); multiple factors 7 (HCV + Alcohol 6, HCV + hepatotoxic agents 1); acute viral hepatitis (HBV) 3; alcoholism 1; other 5 (2 angioma, 1 hepatocarcinoma, 1 cholelithiasis, 1 hydatid cyst). (II) Serological markers: 1) HBV: a) HBsAG+ 8.4% (HBeAg+ 57.1%) (Co-infection HDV 25%), b) HBsAg- with anti-HBc+ 71.9%, c) HBsAg- with anti-HBc- and anti-HBs+ 0.9% (no previous vaccination). 2) HCV 62.3% (we exclude the patients with EIA+ and a second-generation RIBA test indeterminate or negative). CONCLUSIONS: 1) Hepatobiliary complications are common in HIV-patients (73%). 2) Chronic viral hepatitis HCV is the most frequent disease. 3) In our experience, serological markers of HBV and HCV are detected in 81.2% (8.4% with HBsAg+) and 62.3% respectively.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Alanine Transaminase
• Carcinoma, Hepatocellular
• HIV Infections
• HIV Seropositivity
• Hepacivirus
• Hepatitis, Chronic
• Hepatitis, Viral, Human
• Humans
• Prospective Studies

Other ID:

• 95920812

UI: 102213755

From Meeting Abstracts